Pharmaceutical and healthcare report offering, “Bronchitis – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global bronchitis market. The report identifies the key trends shaping and driving the global bronchitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global bronchitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.The global bronchitis market was valued at $482m in 2009 and is forecast to grow by 3.7% annually for the next seven years. The typical form of bronchitis is self-limited. The bronchitis market is characterized by many generics and OTC. The NSAIDS, cough suppressants and antipyretics are mere supportive therapies. Antibiotics are highly prescribed to treat atypical form of the disease. The increase in the market size is attributed to the increase in incidence and increase in the up take of cost effective drugs

There are 13 molecules in the various phases of the developmental pipeline. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. The antibiotics in the pipeline are generic. Upon approval they will add to the competition. The phase of the pipeline consists of levefloxacin and Merck’s Singulair. Upon approval they are expected to intensify the competition

Scope

The scope of the report includes:

• Annualized global bronchitis market revenues data from 2001 to 2009, forecast for seven years to 2016.
• Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include alpha 1 adrenergic receptors agonist, beta (2)-adrenergic agonist,, anti-inflammatory, inhibitor topoisomerase IV DNA gyrase, glucocorticoid agonist leukotriene D4 antagonist and loop diuretic
• Analysis of the current and future market competition in the global bronchitis market. The key market players covered are Merck and Co and Johnson & Johnson Pharmaceutical Research & Development, Pfizer and Merck & Co.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future bronchitis market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global bronchitis market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global bronchitis market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global bronchitis market landscape? – Identify, understand and capitalize.

Companies Mentioned

Merck & Co., Inc
Pfizer Inc.
Abbott Laboratories
Johnson & Johnson

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3185/Bronchitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical and healthcare report,” Allergic Conjunctivitis – Drug Pipeline Analysis and Market Forecasts to 2016” provides essential source of information and analysis on the global allergic conjunctivitis market. The report identifies the key trends shaping and driving the global allergic conjunctivitis market. The report also provides insights into the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights into the pipeline products within the global allergic conjunctivitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current allergic conjunctivitis market is dominated by brands, generics and off-label formulations which have high patient affordability, and there is strong competition. The pipeline for allergic conjunctivitis lacks innovation and has 17 molecules in clinical development. Allergic conjunctivitis market has low unmet needs as the market is well served by the currently available different treatment options from different classes of therapies

Scope

The scope of the report includes:

• Annualized global allergic conjunctivitis market revenues data from 2001 to 2009, forecast for seven years to 2016.
• Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include antihistamines/anti-allergic drugs which account for the largest share of the pipeline fallowed by immunosuppressants, NSAIDs, immunotherapy and PDE4 (Phosphodiesterase type 4) inhibitors.
• Analysis of the current and future market competition in the global allergic conjunctivitis market. The key market players covered are Novagali Pharma SA, Fovea Pharmaceuticals SA, Cytos Biotechnology AG and Ono Pharmaceutical Co. Ltd.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future allergic conjunctivitis market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global allergic conjunctivitis market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global allergic conjunctivitis market landscape? – Identify, understand and capitalize.

Companies Mentioned

Novagali Pharma S.A
Fovea Pharmaceuticals SA
Cytos Biotechnology AG
Ono Pharmaceutical Co. Ltd

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3184/Allergic-Conjunctivitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global hemophilia market was valued at $6.5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX.

Scope

The scope of the report includes:

• Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016.
• Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII.
• Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N.V., Novo Nordisk.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global haemophilia market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global haemophilia market landscape? – Identify, understand and capitalize.

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3183/Hemophilia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical and healthcare report offering, “Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016”. is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global pneumonia market was worth $1.4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4.3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increases in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market.

Scope

The scope of the report includes:

• Annualized global pneumonia market revenues data from 2000 to 2009, forecast for seven years to 2016.
• Key geographies covered in this report include the Unites States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action are cell wall synthesis inhibitors, protein synthesis inhibitors and topoisomerase II and topoisomerase IV inhibitors.
• Analysis of the current and future market competition in the global pneumonia market. The key market players covered are AstraZeneca, Pfizer, Bayer, GSK and J&J Pharmaceuticals.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future pneumonia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global pneumonia market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global pneumonia market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global pneumonia market landscape? – Identify, understand and capitalize.

Companies Mentioned

Forest Laboratories, Inc
Basilea Pharmaceutica
Advanced Life Sciences
Theravance, Inc

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3182/Pneumonia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

GlobalData has released a pharmaceutical and healthcare report, “Hepatitis C – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global hepatitis C market. The report identifies the key trends shaping and driving the global hepatitis C market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to cause significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global hepatitis C sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

GlobalData forecasts the global hepatitis C market to grow at 9.8% annually for the next seven years to reach $8.5 billion by 2016. This growth is primarily attributed to high unmet need in the market which is expected to be served by strong pipeline candidates. The growth will be further supported by the prevalence of the disease. GlobalData has concluded that the global hepatitis C market is underserved by the current product options and so there is significant scope for new entrants to capture value from underserved segments. Designing products with curative properties, high safety profiles and better patient compliance is one of key challenges for this market and could provide a significant market share for any company.

Scope

The scope of the report includes:

• Annualized global hepatitis C market revenues data from 2000 to 2009, forecast for seven years to 2016.
• Key geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include protease inhibitors, polymerase inhibitors, toll receptor agonists, drugs with interferon-like actions, HCV inhibitors and immunomodulators.
• Analysis of the current and future market competition in the global hepatitis C market. The key market players covered are Merck, Human Genome Sciences, Novartis, Vertex, Janssen, Mitsubishi, Tibotec and Roche.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future hepatitis C market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis C market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global hepatitis C market landscape? – Identify, understand and capitalize.

Companies Mentioned

Merck & Co
F. Hoffmann-La Roche and Pharmasset
Human Genome Sciences and Novartis
Vertex Pharmaceuticals and Tibotec
Pharmaceuticals

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3181/Hepatitis-C-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical and healthcare report, “Stomach Cancer – Drug Pipeline Analysis and Market Forecasts to 2016”, is an essential source of information and analysis on the global stomach cancer market. The report identifies the key trends shaping and driving the global stomach cancer market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products in the global stomach cancer segment.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global gastric cancer market is expected to value $1,313m in 2016. Most of the chemotherapies are already off-patent while Taxotere and Xeloda are expected to lose their patents during 2010 to 2011. Taxotere’s generic version, produced by Hospira, has already been approved in Europe through the decentralized procedure. The market is expected to be driven by the increase in demand due to the launch of promising targeted therapies currently in the late stage of development. The pending approval of Herceptin in the US and Japan will also boost the revenues generated in the gastric cancer market. However, the new therapies are not expected go off-patent before 2016. Therefore, the market is expected to witness strong growth in market revenues in the forecast period.

Scope

The scope of the report includes:

• Annualized global (gastrointestinal) stomach cancer market revenues data from 2001 to 2009, forecast for seven years to 2016.
• Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data split across different phases by mechanism of action and emerging trends. The key classes of mechanism of action are mTOR inhibitors, PARP inhibitors, microtubule inhibitors, VEGFR inhibitors, multiple tyrosine kinase inhibitors, Heat Shock Protein 90 inhibitors, Eg5 inhibitors, Farnesyl-OH-transferase inhibitors, angiogenesis inhibitors and combinations of several existing chemotherapies.
• Analysis of the current and future competition in the global stomach cancer market. The key market players covered include GlaxoSmithKline, Novartis Pharmaceuticals, Merck & Co, Eli Lilly and Company, Amgen, Fresenius Biotech GmBH, ACT Biotech, Genta Incorporated and Bristol Myers-Squibb.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future stomach cancer market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global gastrointestinal (stomach) cancer market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global gastrointestinal (stomach) cancer market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global gastrointestinal (stomach) cancer market landscape? – Identify, understand and capitalize.

Companies Mentioned

GlaxoSmithKline
Novartis Pharmaceuticals
Eli Lilly and Company
Merck & Co

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3180/Stomach-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Summary

The leading business intelligence provider, has released its latest research, “Top 10 Biotechnology Companies – SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline”, which provides an insight into the global biotechnology industry and analyzes the competitive positioning of the top 10 companies in the industry. This pharmaceutical and healthcare report estimates the market size of the global biotechnology industry and its future prospects. It benchmarks the leading companies in the biotechnology industry on selected parameters to analyze their competitive positioning in the market. The report analyzes the future landscape of the biotechnology industry by forecasting the revenues of leading companies to 2012. For each company the report analyzes the financial strength, product portfolio, pipeline strength and therapeutic focus of its R&D activities. It critically examines the strengths and weaknesses of individual companies and the opportunities and threats facing them.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The report analyses the competitive landscape of the biotechnology industry, R&D strategies and pipeline of the top 10 players, and strengths, weaknesses, opportunities and threats facing these companies. Its scope includes
- Market size of the global biotechnology industry and coverage of the changing competitive landscape from 2008 to 2012.
- Review of key industry drivers and restraints which are likely to impact the global biotechnology industry in the future.
- Analysis of the competitive positioning of the top 10 biotechnology companies globally.
- Analysis of pipeline products in the global biotech market by therapy area like cancer, infectious diseases, respiratory disorders, autoimmune disorders, and product classes.
- Financial analysis including annual revenues of top 10 companies from 2004 to 2008, with forecasts to 2012.
- SWOT analysis, DuPont analysis and financial benchmarking of the top 10 biotech companies.
- Analysis of the therapeutic focus, marketed products and product pipeline of top 10 biotech companies.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop a clear knowledge and understanding of the competitive landscape and how this will change in the coming years.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Effectively plan your M&A and partnership strategies by identifying companies with the most promising pipeline.
- Make more informed business decisions from the insightful and in-depth analysis of the key strategies to be followed by competitors.
- Effectively plan your investment strategies by identifying companies with maximum investment potential.
- Identify key winners and losers and who is best positioned to take advantage of the emerging market opportunities.

Companies Mentioned

Amgen
Genentech (Roche)
Gilead Sciences
UCB Pharma
Genzyme
Biogen Idec
CSL Limited
Celgene
Cephalon
Actelion

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1208/Top-10-Biotechnology-Companies-SWOT-Analysis-Competitive-Benchmarking-Financial-Analysis-and-R-D-Pipeline.html

Contact us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Summary

“The Future of the Neurology Devices Market to 2016 – Market Forecasts, Competitive Landscape and Pipeline Analysis” provides key data, information and analysis on the global neurology devices market, a key segment within the medical device industry. This medical device report provides market landscape, competitive landscape and market trends information on five neurology devices market categories – CSF Management, Neurosurgical Products, Neurostimulation Devices, Interventional Neurology and Radiosurgery. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

- Key geographies covered include the US (United States), Canada, the UK (United Kingdom), Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Market size and company share data for five neurology devices market categories – Cerebro Spinal Fluid (CSF) Management, Neurosurgical Products, Neurostimulation Devices, Interventional Neurology and Radiosurgery.
- Annualized market revenues data from 2002 to 2009, forecast forward for 7 years to 2016. Company shares data for 2008.
- Qualitative analysis of key market trends, market drivers, and restraints by each category within the neurology devices market.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.
- Key players covered include Medtronic, Boston Scientific, Cordis, St. Jude Medical, Cyberonics, ev3, Elekta, Accuray, B. Braun, and Codman & Shurtleff.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the neurology devices market globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next being thing in the neurology devices market landscape? – Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global neurology devices market and the factors shaping it.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1478/The-Future-of-the-Neurology-Devices-Market-to-2016-%E2%80%93-Market-Forecasts-Competitive-Landscape-and-Pipeline-Analysis.html

Contact us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

“The Future of the Home Healthcare Equipment Market to 2016 – Increasing Awareness Driving Demand” provides key data, information and analysis on the global home healthcare equipment market. The report provides market landscape, competitive landscape and market trends information on seven home healthcare equipment market segments – glucose monitoring systems, insulin delivery devices, inhalation systems, hematology rapid tests, automatic sphygmomanometers and remote patient monitoring. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.

Scope

- Key geographies covered include the US (United States), Canada, the UK (United Kingdom), Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.
- Market size and company share data for seven home healthcare equipment market categories – glucose monitoring systems, insulin delivery devices, inhalation systems, hematology rapid tests, automatic sphygmomanometers and remote patient monitoring.
- Annualized market revenues data from 2002 to 2009, forecast forward for 7 years to 2016. Company shares data for 2008
- Qualitative analysis of key market trends, market drivers, and restraints by each category within the home healthcare equipment market.
- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the home healthcare equipment market globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What’s the next being thing in the home healthcare equipment market landscape? – Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the global home healthcare equipment market and the factors shaping it.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1955/The-Future-of-the-Home-Healthcare-Equipment-Market-to-2016-Market-Forecasts-Competitive-Landscape-and-Pipeline-Analysis.html

Contact us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

The industry analysis specialist’s new report, “Endometriosis – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global endometriosis market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global endometriosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global endometriosis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global endometriosis market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global endometriosis market. Key companies covered include Bayer AG, Pfizer, Aeterna Zentaris, Neurocrine Biosciences Inc., KV Pharmaceutical company.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with endometriosis.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global endometriosis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global endometriosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global endometriosis market landscape? – Identify, understand and capitalize.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1143/Endometriosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html

Contact Us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com